- €189.42m
- €98.76m
- €6.86m
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs
Brief: Transgene FY Operating Income EUR -35.1 Million
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Transgene Says Tg4001 Phase II Study Fails To Meet Primary Objective
Brief: Transgene: First Patient Enrolled In Phase II Clinical Trial Of Cancer Vaccine TG4050
Brief: Transgene Expects New Clinical Data On TG4001, TG6050 And BT-001 In H2
Brief: Transgene, NEC Present First Data On Neoantigen Cancer Vaccine
Brief: Transgene Anticipates Significant Progress From Immunotherapy Pipeline In 2024
Brief: Transgene Appoints Lucie Larguier As CFO
Brief: Transgene, NEC Extend Collaboration On Clinical Development Of Neoantigen Cancer Vaccine TG4050
Brief: Transgene Announces Appointment Of Arnaud Dubarry As CFO
Brief: Transgene/Bioinvent: First Patient Treated In Part B Phase I Trial BT-001 In Combination With Keytruda®
Brief: Transgene SA Plans To Commence A Randomized Phase Ii Trial In Head And Neck Cancer With Tg4050 In 2024
Brief: Euronext Announces Results Of Annual Review For CAC Family Indices
Brief: One Biosciences Announces The Appointment Of Hedi Ben Brahim As Chief Executive Officer
Brief: Transgene Gets $15.3 Mln From Sale Of Securities Held For Sale